ORIGINAL RESEARCH article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1636358
This article is part of the Research TopicBladder Cancer Awareness Month 2025: Current Developments and Insights in the Treatment of Bladder CancerView all 4 articles
Multimodal Prognostic Models for Bladder Urothelial Carcinoma: Uroplakin III Combined with Serum and Demographic Data
Provisionally accepted
- 1The Second Affiliated Hospital of Kunming Medical University, Kunming, China
- 2First Affiliated Hospital of Kunming Medical University, Kunming, China
- 3The Third People's Hospital of Kunming, Kunming, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Bladder urothelial carcinoma (BUC) remains a highly recurrent and heterogeneous malignancy. Accurate postoperative risk stratification is crucial to guide adjuvant therapy decisions. We hypothesized that integrating Uroplakin III （UPK3A protein）protein expression with systemic inflammation markers and demographic factors could improve prognostic prediction through advanced machine learning(ML) models. Methods:This retrospective study analyzed 1,032 BUC patients who underwent radical cystectomy. Clinical, pathological, and serological data, including immunohistochemical UPK3A protein expression, were collected. Least Absolute Shrinkage and Selection Operator (LASSO) regression with λ=0.009 (determined via 10-fold cross-validation) was used for feature selection. Nine ML models were trained and validated. Model performance was assessed using Area Under the Receiver Operating Characteristic Curve (AUC-ROC), calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC). Model interpretability was evaluated with SHapley Additive exPlanations (SHAP). Results: Light Gradient Boosting Machine(LightGBM), Random Forest(RF), and Extreme Gradient Boosting (XGBoost) models demonstrated superior performance (AUCs: 0.894/0.754 for RF in training/test sets). SHAP analysis highlighted vascular invasion, tumor necrosis, and UPK3A protein as key predictors. CIC demonstrated strong clinical utility. Integrating UPK3A protein with inflammatory and demographic variables outperformed traditional models. Conclusions: The combination of UPK3A protein expression with multimodal features significantly enhances prognostic modeling in BUC. This approach offers a promising clinical decision support tool to stratify risk and guide postoperative management. Future studies should incorporate transcriptomic/proteomic data to further validate these findings. Keywords:BUC; UPK3A protein; Prognostic Prediction; ML; Serum Inflammatory Markers; Risk Stratification; SHAP; Multimodal Data
Keywords: BUC, UPK3A protein, Prognostic prediction, ML, serum inflammatory markers, risk stratification, Shap, Multimodal data
Received: 27 May 2025; Accepted: 11 Aug 2025.
Copyright: © 2025 Feng, Jian, Tao, Wang, Li, Dong and Wenlin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tai Wenlin, The Second Affiliated Hospital of Kunming Medical University, Kunming, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.